Effects of GLP-1 receptor agonist treatment on pulmonary function and quality of life in obese patients with chronic obstructive pulmonary disease - A prospective, randomized, placebo-controlled, double-blinded, parallel group, two-center trial for the evaluation of the effect of Liraglutide 3 mg daily on chronic obstructive pulmonary disease. - Liraglutide in COPD

Hospital of South West Jutland0 个研究点目标入组 40 人开始时间: 2017年11月22日最近更新: 2020年4月29日

适应症

试验速览

暂无简介。

•1.Informed consent obtained before any trial-related activities
•2.COPD as defined by FEV1/FVC<70% after maximal broncho-dilatation and in accordance with the Gold guidelines 2017 (25)
•3.Previous smoking of = 20 pack-years
•4.Overweight defined as BMI > 27 kg/m2
•5.Age 30 – 75 years
•6.Women of childbearing potential must use a safe anti-contraceptive method
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•1.Chronic treatment with systemic steroids (inhalation steroids allowed)
•2.Current smokers
•3.Diabetes mellitus type 1 and type 2 as defined by current or previous treatment with antidiabetic medications of any kind or HbA1c = 48mmol/mol
•4.Severe hepatic disease (Alanine transferase > 3 x UNL)
•5.Severe impaired renal function (eGFR < 30ml/min)
•6.Congestive heart disease NYHA class 3-4
•7.History of acute or chronic pancreatitis
•8.History of cholecystitis or cholecystolithiasis
•9.Pregnant or breastfeeding women
•10.Known bronchial asthma or interstitial lung disease
•11.Family history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma
•12.Large goiter or plasma-calcitonin > 50ng/ml

发起方

Hospital of South West Jutland